查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081500

生物相似藥市場：2026-2032年全球市場預測（依產品類型、治療領域、給藥途徑、研發階段、生產技術、最終用戶和分銷管道分類）

Biosimilars Market by Product Type, Therapeutic Area, Route Of Administration, Development Stage, Manufacturing Technology, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，生物相似藥市場將成長至 712.4 億美元，複合年成長率為 10.73%。

主要市場統計數據
基準年 2025 348.9億美元
預計年份：2026年 385億美元
預測年份 2032 712.4億美元
複合年成長率 (%) 10.73%

生物相似藥市場執行摘要

生物相似藥正在革新生技藥品的獲取途徑，在已通過核准的參考生技藥品的獨佔期結束後，它們可以提供高度相似的替代品。與小分子學名藥不同，生物相似藥需要大量的分析、非臨床和臨床證據，因為生技藥品是在生物體內生產的，本身就具有變異性。

生物相似藥產業的變革

生物相似藥市場正從早期監管檢驗階段邁向競爭性商業化階段。針對Adalimumab、曲妥Bevacizumab單抗、貝伐Rituximab單抗、利妥昔單抗、促紅血球生成素、非格司亭、培非格Pegfilgrastim和甘精胰島素等昂貴生物製藥的多種生物類似藥表明，如果醫保報銷機制支持替代、競標和納入處方藥目錄，生物類似藥之間的競爭可以擴大患者的生物製藥

人工智慧對生物相似藥的累積影響

人工智慧 (AI) 並非取代監管證據要求，而是為整個生物相似藥價值鏈帶來累積效益。 AI 驅動的分析可以輔助細胞株篩檢、最佳化上下游製程、蛋白質表徵、雜質模式檢測以及批間比較評估。這些功能尤其重要，因為生物相似藥的成功取決於對糖基化、效力、純度、聚集性和穩定性等關鍵品質屬性的高精度控制。

生物相似藥的關鍵區域見解

亞太地區是生物相似藥的主要成長引擎，這得益於該地區未接受治療的患者數量龐大、生物製藥的可及性不斷擴大，以及印度、中國和韓國強大的生產基地。中國國家藥品監督管理局正在加強對生物相似藥的指導，印度擁有成熟的生物相似藥核准途徑，韓國則建立了全球公認的生物製藥生產能力。在日本和澳大利亞，嚴格的監管和保險報銷機制進一步推動了以品質為導向的生物相似藥在腫瘤學、免疫學、糖尿病和支持性治療領域的應用。

全球生物相似藥市場關鍵群體分析

在東南亞國協，監管的逐步協調、「信賴路徑」以及腫瘤、糖尿病、腎臟病和自體免疫疾病領域對價格合理的生物製藥的需求，都為生物製劑的發展提供了有利條件。該地區的醫療衛生系統正擴大使用生物相似藥來擴大治療覆蓋範圍，同時兼顧品質保證和採購效率。在海灣合作理事會國家，透過集中採購、處方藥目錄管理、保險制度改革和醫療衛生系統現代化，生物相似藥的可及性正在提高，本地生物製藥製劑的生產能力和供應穩定性也在提升。

影響生物相似藥採用的主要國家趨勢

美國是生物相似藥最大的商業性戰場，其推廣應用受到支付方協議、FDA互換性政策、各州替代藥物法律、專科藥房的經濟狀況以及生物相似藥對重磅生技藥品的競爭影響等因素的影響。在加拿大，省級轉換舉措和公共醫療福利計劃政策正在加速推動生物相似藥的推廣應用。同時，墨西哥和巴西正在拓展生物相似藥的推廣管道，以滿足患者對藥物可及性、治療可及性和公共採購的需求。巴西的醫療監管機構已製定等效性要求，該國的公共醫療體系仍然是獲取生物製藥的關鍵管道。

為生物相似藥產業領導者提供的實用建議

產業領導者應優先考慮科學可靠的等效性數據、擴充性的生產系統和透明的品管系統。生物相似藥的成功取決於關鍵品質特性的一致性、跨多個司法管轄區的監管合規準備，以及在上市前解決支付方、醫生、藥劑師和患者顧慮的上市策略。

調查方法

本執行摘要是透過對已核實的公開資源進行二手資料研究和檢驗整合而編寫的，這些資源包括監管記錄、生物類似藥核准資料庫、衛生技術評估指南、政策文件、同行評審文獻、藥物安全監測指南以及公開的報銷和競標資訊來源。主要參考文獻包括美國食品藥物管理局 (FDA)、歐洲藥品管理局 (EMA)、世界衛生組織 (WHO)、各國監管機構、公共衛生機構以及公開的真實世界證據資訊來源。

結論

生物相似藥正從成本控制工具轉變為支撐生物製藥可及性的策略支柱。在監管清晰、生產可靠性高、支付方合作、處方醫生信任度高以及病患支持相互促進的領域，生物相似藥的發展機會最為顯著。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：生物相似藥市場：依產品類型分類

  • 單株抗體
    • 抗TNF製劑
    • 抗CD20製劑
    • 抗 VEGF 藥物
  • 重組激素和生長因子
    • 胰島素及其類似物
    • 顆粒細胞增生因子
    • 促紅細胞生成素
  • 融合蛋白
  • 胜肽

第8章：生物相似藥市場：依治療領域分類

  • 腫瘤學
    • 乳癌
    • 結腸癌
    • 肺癌
    • 骨髓惡性腫瘤
  • 自體免疫/發炎性疾病
    • 類風濕性關節炎
    • 銀屑病和乾癬性關節炎
    • 發炎性腸道疾病
      • 克隆氏症
      • 潰瘍性大腸炎
    • 僵直性脊椎炎
  • 內分泌/代謝
  • 血液學
    • 嗜中性白血球低下症
    • 化療引起的貧血
  • 不孕不育及生殖醫學
  • 眼科
  • 神經病學

第9章：生物相似藥市場：依給藥途徑分類

  • 靜脈
  • 皮下
  • 肌肉內部

第10章：生物相似藥市場：依研發階段分類

  • 藥物發現和臨床前階段
  • 臨床開發
    • 第一階段
    • 第二階段
    • 第三階段
  • 規章制度和核准
  • 商業化

第11章：生物相似藥市場：依生產技術分類

  • 重組DNA技術
  • 細胞培養系統
  • 微生物表現系統
    • 大腸桿菌
    • 東方
  • 蛋白質純化和配方
  • 分析與表徵平台

第12章：生物相似藥市場：依最終用戶分類

  • 醫院
  • 專科診所
  • 研究和學術機構
  • 居家照護環境

第13章：生物相似藥市場：依通路分類

  • 線上
  • 離線

第14章：生物相似藥市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：生物相似藥市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：生物相似藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Alvotech SA
  • Amgen Inc.
  • Apobiologix
  • Apotex Inc.
  • Biocon Limited
  • BioFactura, Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc
  • Celltrion Healthcare Co.,Ltd.
  • Coherus BioSciences
  • Dr. Reddy's Laboratories Limited
  • Eden Biologics, Inc.
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi
  • Innovent Biologics, Inc.
  • Intas Pharmaceuticals Ltd.
  • Kashiv BioSciences, LLC.
  • Merck KGaA
  • NeuClone
  • Nippon Kayaku Co., Ltd.
  • Novartis AG
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sanofi SA
  • Shanghai Henlius Biotech, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-4358917D6590

The Biosimilars Market is projected to grow by USD 71.24 billion at a CAGR of 10.73% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 34.89 billion
Estimated Year [2026] USD 38.50 billion
Forecast Year [2032] USD 71.24 billion
CAGR (%) 10.73%

Biosimilars Market Executive Summary

Biosimilars are reshaping biologic drug access by offering highly similar alternatives to approved reference biologics after exclusivity periods expire. Unlike small-molecule generics, biosimilars require extensive analytical, nonclinical, and clinical evidence because biologics are manufactured in living systems and are inherently variable.

Regulatory maturity is driving confidence. The European Medicines Agency approved the first biosimilar in 2006, while the U.S. Food and Drug Administration approved its first biosimilar in 2015 under the Biologics Price Competition and Innovation Act pathway. The World Health Organization has also supported global regulatory convergence through guidance on similar biotherapeutic products. Today, biosimilars are central to strategies focused on oncology, immunology, endocrinology, ophthalmology, nephrology, and supportive care, with adoption shaped by payer incentives, physician trust, manufacturing scale, pharmacovigilance discipline, and patient education.

Transformative Shifts in the Biosimilars Landscape

The biosimilars landscape is shifting from early regulatory validation to competitive commercialization. Multiple biosimilars for high-spend biologics, including adalimumab, trastuzumab, bevacizumab, rituximab, epoetin, filgrastim, pegfilgrastim, and insulin glargine, have demonstrated that biosimilar competition can broaden patient access and pressure biologic spending when reimbursement systems support substitution, tendering, and formulary uptake.

Manufacturers are also moving beyond launch timing and price discounting. Competitive advantage increasingly depends on reliable supply, device usability, interchangeability strategies where applicable, real-world evidence, prescriber education, and lifecycle planning. As biologic patent expirations continue across monoclonal antibodies, fusion proteins, insulins, and complex biologics, organizations with advanced comparability science, global regulatory expertise, and cost-efficient manufacturing networks are better positioned to capture sustained value.

Cumulative Impact of Artificial Intelligence on Biosimilars

Artificial intelligence is creating cumulative gains across the biosimilar value chain rather than replacing regulatory evidence requirements. AI-enabled analytics can support cell-line screening, upstream and downstream process optimization, protein characterization, impurity pattern detection, and batch-to-batch comparability assessment. These capabilities are especially valuable because biosimilar success depends on controlling critical quality attributes, including glycosylation, potency, purity, aggregation, and stability, with high precision.

AI is also improving clinical development and post-market monitoring. Machine learning can identify appropriate patient cohorts, optimize trial operations, detect pharmacovigilance signals, and analyze real-world outcomes from claims, registries, and electronic health records. The impact is strongest when AI systems are validated, auditable, explainable, and aligned with Good Manufacturing Practice, data integrity, cybersecurity, and evolving regulatory expectations for advanced analytics in regulated life sciences environments.

Key Regional Insights for Biosimilars

Asia-Pacific is a major growth engine for biosimilars due to large treatment-naive populations, expanding biologics access, and strong manufacturing bases in India, China, and South Korea. China's National Medical Products Administration has strengthened biosimilar guidance, India has long-standing similar biologics pathways, and South Korea has built globally recognized biologics manufacturing capabilities. Japan and Australia add regulatory rigor and reimbursement discipline, supporting quality-led adoption across oncology, immunology, diabetes, and supportive care.

North America remains commercially influential, led by the United States and Canada. U.S. biosimilar uptake is shaped by FDA approvals, interchangeability designations, payer contracting, pharmacy benefit dynamics, specialty pharmacy channels, and provider confidence, while Canadian provinces have used switching policies to expand savings and increase biosimilar utilization in publicly funded systems. Europe continues to be the most mature biosimilar environment, supported by EMA experience since 2006, national tenders, therapeutic switching experience, and physician familiarity built through years of post-approval evidence.

Latin America is advancing through ANVISA, COFEPRIS, and other national regulatory frameworks, though access varies by reimbursement capacity, local procurement systems, and public-sector funding. The Middle East is investing in biologics localization, particularly in Saudi Arabia and the UAE, where health-system modernization and procurement reform are improving access to complex medicines. Africa shows long-term potential, with South Africa, Egypt, and Morocco serving as important regulatory and manufacturing reference points as reliance mechanisms, WHO-aligned standards, and essential medicine access initiatives evolve.

Key Group Insights Across Global Biosimilar Markets

ASEAN markets are benefiting from gradual regulatory alignment, reliance pathways, and demand for affordable biologics across oncology, diabetes, renal care, and autoimmune disease. Health systems in the region are increasingly using biosimilars to expand treatment access while balancing quality assurance and procurement efficiency. GCC countries are using centralized procurement, formulary management, insurance reform, and health-system modernization to improve biosimilar access while encouraging local biologics capability and supply security.

The European Union remains the benchmark group for biosimilar regulation due to the EMA's long-standing scientific framework, member-state pharmacovigilance systems, and extensive real-world experience with switching and tender-driven adoption. BRICS economies combine large patient populations with manufacturing ambition, making them central to future biosimilar supply, demand, and localization strategies. G7 markets shape global standards through regulatory science, intellectual property policy, health-technology assessment, reimbursement models, and pharmacovigilance expectations. NATO is not a medicines regulator, but its member economies increasingly view pharmaceutical supply resilience, biologics manufacturing capacity, and medical countermeasure readiness as part of broader health-security planning.

Key Country Insights Shaping Biosimilar Adoption

The United States is the largest commercial battleground for biosimilars, with adoption influenced by payer contracting, FDA interchangeability policy, state substitution laws, specialty pharmacy economics, and the competitive impact of biosimilars for blockbuster biologics. Canada has accelerated uptake through provincial switching initiatives and public drug plan policies, while Mexico and Brazil are expanding biosimilar pathways to address affordability, therapeutic access, and public procurement needs. Brazil's health regulator has established comparability requirements, and the country's public health system remains an important channel for biologic access.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established biosimilar experience, although tender design, prescribing incentives, hospital procurement, and physician engagement differ by country. Germany has used physician-level prescribing frameworks and rebate mechanisms, the United Kingdom has supported biosimilar uptake through national health-system guidance, and France, Italy, and Spain continue to refine substitution, tendering, and regional access approaches. Russia continues to emphasize domestic biologics production and import substitution to improve medicine security.

China and India are pivotal manufacturing and demand centers, supported by large patient populations, expanding biologics use, and domestic regulatory pathways for similar biologics. Japan prioritizes stringent quality expectations, post-marketing surveillance, and reimbursement controls, while Australia supports biosimilar prescribing through policy incentives and public reimbursement mechanisms. South Korea stands out for export-oriented biosimilar manufacturing, strong bioprocessing capability, and regulatory experience that supports participation in global biosimilar supply chains.

Actionable Recommendations for Biosimilar Industry Leaders

Industry leaders should prioritize scientifically robust comparability packages, scalable manufacturing, and transparent quality systems. Biosimilar success depends on consistent critical quality attributes, regulatory readiness across multiple jurisdictions, and a launch strategy that addresses payer, physician, pharmacist, and patient concerns before market entry.

Organizations should invest in real-world evidence, pharmacovigilance infrastructure, device and administration improvements, cold-chain resilience, and supply continuity planning. Partnerships with local manufacturers, distributors, contract development and manufacturing organizations, and health systems can accelerate access in emerging markets. Leaders should also prepare for intensified price competition by differentiating on reliability, service support, education, portfolio breadth, and therapeutic depth rather than discounting alone.

Research Methodology

This executive summary is developed through secondary research and analytical synthesis using verified public sources, including regulatory agency records, biosimilar approval databases, health-technology assessment guidance, policy documents, peer-reviewed literature, pharmacovigilance guidance, and publicly available reimbursement and tender information. Key reference points include FDA, EMA, WHO, national regulatory authorities, public health agencies, and published real-world evidence sources.

The methodology evaluates market dynamics across regulation, manufacturing, commercialization, therapeutic application, geographic adoption, procurement policy, and competitive behavior. Insights are validated by cross-checking regulatory milestones, approval trends, policy actions, reimbursement decisions, and real-world adoption signals. The analysis avoids speculative claims and emphasizes evidence-based interpretation of biosimilar market development without market sizing, market share estimates, or forecasting.

Conclusion

Biosimilars are moving from a cost-containment tool to a strategic pillar of biologic medicine access. The strongest opportunities are emerging where regulatory clarity, manufacturing reliability, payer alignment, prescriber confidence, and patient support reinforce one another.

Future leadership will be defined by organizations that combine advanced analytical science, efficient production, AI-enabled process intelligence, disciplined pharmacovigilance, and region-specific commercialization models. As more biologic exclusivities expire, biosimilars are expected to play a larger role in improving affordability, expanding treatment access, and strengthening global biologics supply resilience.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Biosimilars Market, by Product Type

  • 7.1. Monoclonal Antibodies
    • 7.1.1. Anti-TNF Agents
    • 7.1.2. Anti-CD20 Agents
    • 7.1.3. Anti-VEGF Agents
  • 7.2. Recombinant Hormones & Growth Factors
    • 7.2.1. Insulin & Analogues
    • 7.2.2. Granulocyte Colony-Stimulating Factors
    • 7.2.3. Erythropoiesis-Stimulating Agents
  • 7.3. Fusion Proteins
  • 7.4. Peptides

8. Biosimilars Market, by Therapeutic Area

  • 8.1. Oncology
    • 8.1.1. Breast Cancer
    • 8.1.2. Colorectal Cancer
    • 8.1.3. Lung Cancer
    • 8.1.4. Hematologic Malignancies
  • 8.2. Autoimmune & Inflammatory
    • 8.2.1. Rheumatoid Arthritis
    • 8.2.2. Psoriasis & Psoriatic Arthritis
    • 8.2.3. Inflammatory Bowel Disease
      • 8.2.3.1. Crohns Disease
      • 8.2.3.2. Ulcerative Colitis
    • 8.2.4. Ankylosing Spondylitis
  • 8.3. Endocrinology & Metabolism
  • 8.4. Hematology
    • 8.4.1. Neutropenia
    • 8.4.2. Chemotherapy-Induced Anemia
  • 8.5. Fertility & Reproductive Health
  • 8.6. Ophthalmology
  • 8.7. Neurology

9. Biosimilars Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Subcutaneous
  • 9.3. Intramuscular

10. Biosimilars Market, by Development Stage

  • 10.1. Discovery & Preclinical
  • 10.2. Clinical Development
    • 10.2.1. Phase I
    • 10.2.2. Phase II
    • 10.2.3. Phase III
  • 10.3. Regulatory & Approval
  • 10.4. Commercialization

11. Biosimilars Market, by Manufacturing Technology

  • 11.1. Recombinant DNA Technology
  • 11.2. Cell Culture Systems
  • 11.3. Microbial Expression Systems
    • 11.3.1. Escherichia Coli
    • 11.3.2. Yeast
  • 11.4. Protein Purification & Formulation
  • 11.5. Analytical & Characterization Platforms

12. Biosimilars Market, by End User

  • 12.1. Hospitals
  • 12.2. Specialty Clinics
  • 12.3. Research & Academic Institutes
  • 12.4. Homecare Settings

13. Biosimilars Market, by Distribution Channel

  • 13.1. Online
  • 13.2. Offline

14. Biosimilars Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Biosimilars Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Biosimilars Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Alvotech S.A
  • 18.2. Amgen Inc.
  • 18.3. Apobiologix
  • 18.4. Apotex Inc.
  • 18.5. Biocon Limited
  • 18.6. BioFactura, Inc.
  • 18.7. Biogen Inc.
  • 18.8. Boehringer Ingelheim International GmbH
  • 18.9. Catalent, Inc
  • 18.10. Celltrion Healthcare Co.,Ltd.
  • 18.11. Coherus BioSciences
  • 18.12. Dr. Reddy's Laboratories Limited
  • 18.13. Eden Biologics, Inc.
  • 18.14. F. Hoffmann-La Roche AG
  • 18.15. Fresenius Kabi
  • 18.16. Innovent Biologics, Inc.
  • 18.17. Intas Pharmaceuticals Ltd.
  • 18.18. Kashiv BioSciences, LLC.
  • 18.19. Merck KGaA
  • 18.20. NeuClone
  • 18.21. Nippon Kayaku Co., Ltd.
  • 18.22. Novartis AG
  • 18.23. Panacea Biotec Limited
  • 18.24. Pfizer Inc.
  • 18.25. Samsung Bioepis Co., Ltd.
  • 18.26. Sanofi S.A.
  • 18.27. Shanghai Henlius Biotech, Inc.
  • 18.28. Teva Pharmaceutical Industries Ltd.
  • 18.29. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOSIMILARS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BIOSIMILARS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BIOSIMILARS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BIOSIMILARS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL BIOSIMILARS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-TNF AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-TNF AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-TNF AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-CD20 AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-CD20 AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-CD20 AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-VEGF AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-VEGF AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-VEGF AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RECOMBINANT HORMONES & GROWTH FACTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RECOMBINANT HORMONES & GROWTH FACTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RECOMBINANT HORMONES & GROWTH FACTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INSULIN & ANALOGUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INSULIN & ANALOGUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INSULIN & ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GRANULOCYTE COLONY-STIMULATING FACTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GRANULOCYTE COLONY-STIMULATING FACTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GRANULOCYTE COLONY-STIMULATING FACTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ERYTHROPOIESIS-STIMULATING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ERYTHROPOIESIS-STIMULATING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ERYTHROPOIESIS-STIMULATING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FUSION PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FUSION PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FUSION PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AUTOIMMUNE & INFLAMMATORY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AUTOIMMUNE & INFLAMMATORY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AUTOIMMUNE & INFLAMMATORY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PSORIASIS & PSORIATIC ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PSORIASIS & PSORIATIC ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PSORIASIS & PSORIATIC ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CROHNS DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CROHNS DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CROHNS DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENDOCRINOLOGY & METABOLISM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENDOCRINOLOGY & METABOLISM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ENDOCRINOLOGY & METABOLISM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEMATOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HEMATOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEUTROPENIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUTROPENIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHEMOTHERAPY-INDUCED ANEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CHEMOTHERAPY-INDUCED ANEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CHEMOTHERAPY-INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL FERTILITY & REPRODUCTIVE HEALTH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL FERTILITY & REPRODUCTIVE HEALTH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL FERTILITY & REPRODUCTIVE HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DISCOVERY & PRECLINICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DISCOVERY & PRECLINICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DISCOVERY & PRECLINICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CLINICAL DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CLINICAL DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CLINICAL DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PHASE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PHASE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PHASE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL REGULATORY & APPROVAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL REGULATORY & APPROVAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL REGULATORY & APPROVAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL COMMERCIALIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL COMMERCIALIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL COMMERCIALIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL RECOMBINANT DNA TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL RECOMBINANT DNA TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL RECOMBINANT DNA TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL CULTURE SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CELL CULTURE SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELL CULTURE SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL MICROBIAL EXPRESSION SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL MICROBIAL EXPRESSION SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL MICROBIAL EXPRESSION SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ESCHERICHIA COLI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ESCHERICHIA COLI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ESCHERICHIA COLI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL YEAST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL YEAST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL YEAST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PROTEIN PURIFICATION & FORMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PROTEIN PURIFICATION & FORMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL PROTEIN PURIFICATION & FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ANALYTICAL & CHARACTERIZATION PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANALYTICAL & CHARACTERIZATION PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ANALYTICAL & CHARACTERIZATION PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOSIMILARS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE BIOSIMILARS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. GLOBAL BIOSIMILARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN BIOSIMILARS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. GCC BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. GCC BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. GCC BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 282. GCC BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 283. GCC BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 284. GCC BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. GCC BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2018-2032 (USD MILLION)
  • TABLE 286. GCC BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 287. GCC BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 288. GCC BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. GCC BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 290. GCC BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 291. GCC BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. GCC BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 293. GCC BIOSIMILARS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. GCC BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. BRICS BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS BIOSIMILARS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 327. G7 BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 328. G7 BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. G7 BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 330. G7 BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 331. G7 BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 332. G7 BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 333. G7 BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2018-2032 (USD MILLION)
  • TABLE 334. G7 BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 335. G7 BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 336. G7 BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 337. G7 BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 338. G7 BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 339. G7 BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 340. G7 BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 341. G7 BIOSIMILARS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 342. G7 BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 343. NATO BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 344. NATO BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. NATO BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 346. NATO BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 347. NATO BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 348. NATO BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 349. NATO BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2018-2032 (USD MILLION)
  • TABLE 350. NATO BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 351. NATO BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 352. NATO BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 353. NATO BIOSIMILARS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 354. NATO BIOSIMILARS MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 355. NATO BIOSIMILARS MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 356. NATO BIOSIMILARS MARKET SIZE, BY MICROBIAL EXPRESSION SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 357. NATO BIOSIMILARS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 358. NATO BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 359. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 360. UNITED STATES BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 361. UNITED STATES BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 362. UNITED STATES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 363. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES & GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 364. UNITED STATES BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 365. UNITED STATES BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 366. UNITED STATES BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2018-2032 (USD MILLION)
  • TABLE 367. UNITED STATES BIOSIMILARS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2032 (USD MILLION)
  • TABLE 368. UNITED STATES BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 369. UNITED STATES BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRA